aripiprazole has been researched along with Insulin Resistance in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flavin, KS; Newcomer, JW; Nicol, GE; Patterson, BW; Schechtman, KB; Schweiger, JA; Yingling, MD | 1 |
| Belsham, DD; Hahn, MK; Kanagasundaram, P; Kowalchuk, C | 1 |
| Fuller, C; Grudziak, J; Nguyen, HL; Rickels, K; Rickels, MR; Teff, KL | 1 |
| Baker, RA; Citrome, L; Hebden, T; Kalsekar, I | 1 |
| De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
| Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM | 1 |
| Wooten, J | 1 |
2 review(s) available for aripiprazole and Insulin Resistance
| Article | Year |
|---|---|
A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Carbohydrate Metabolism; Diabetes Mellitus; Glucose Metabolism Disorders; Humans; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Overweight; Piperazines; Quinolones; Weight Gain | 2014 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
2 trial(s) available for aripiprazole and Insulin Resistance
| Article | Year |
|---|---|
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.
Topics: Abdominal Fat; Absorptiometry, Photon; Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Insulin Resistance; Intention to Treat Analysis; Male; Mental Disorders; Olanzapine; Problem Behavior; Risperidone; Treatment Outcome | 2018 |
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Humans; Insulin Resistance; Male; Mental Disorders; Olanzapine; Piperazines; Postprandial Period; Quinolones; Weight Gain; Young Adult | 2013 |
4 other study(ies) available for aripiprazole and Insulin Resistance
| Article | Year |
|---|---|
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Cell Line; Clozapine; Energy Metabolism; Hypothalamus; Inflammation; Insulin; Insulin Resistance; MAP Kinase Signaling System; Neurons; Olanzapine; Phosphorylation; Rats; Schizophrenia; Signal Transduction | 2019 |
A case series: evaluation of the metabolic safety of aripiprazole.
Topics: Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sex Factors; Treatment Outcome | 2007 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2007 |